🇺🇸 FDA
Pipeline program

Ixazomib/Pomalidomide/Dexamethasone

IFM 2014-01

Phase 2 small_molecule terminated

Quick answer

Ixazomib/Pomalidomide/Dexamethasone for Multiple Myeloma is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Multiple Myeloma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials